Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.
about
Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents.Almost all antipsychotics result in weight gain: a meta-analysis.The effects of atypical antipsychotic usage duration on serum adiponectin levels and other metabolic parameters.Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factorsAssociation between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patientsEvidence review and clinical guidance for the use of ziprasidone in Canada.Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects.Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine.Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review.Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.Structure and physiological actions of ghrelinYouth, caregiver, and prescriber experiences of antipsychotic-related weight gain.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease.Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics?Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.Effects of weight loss diet therapy on anthropometric measurements and biochemical variables in schizophrenic patients.Recent advances in potential clinical application of ghrelin in obesity.Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment.Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature.Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis.Association of -604G/A and -501A/C Ghrelin and Obestatin Prepropeptide Gene Polymorphisms with Polycystic Ovary Syndrome.Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study.
P2860
Q33257886-756E5CF8-CA76-4B23-9754-AB117013E680Q34502626-10E9E8E3-9262-4F0F-AEA2-A4A55067BE1DQ34661499-91AFC39E-2DAB-4AE8-8629-0D40AC67D9AAQ34666581-0D1A2B00-37C2-40DA-B1B9-CD7C8AB9CFF5Q35566086-0A376F3D-BDC5-4E55-AC8B-C57242067A14Q35864617-2C69DFDC-C7DA-48E0-8EA9-00DAD7D8320EQ35893830-1CB6900B-A192-40BD-8950-8226D4843A93Q36588607-D1594445-DFF6-4BDC-82C0-FB8102E321F6Q36744444-FFF8809A-0D03-4F58-82F6-739538EF0835Q36854018-F9F43BED-151D-4A1C-8AA8-DBA19CFE58CDQ37047473-F82396E3-924D-4B12-A6D1-B693336EE6BEQ37060706-967EE59F-901C-4C71-873B-C3DB56025CABQ37393063-C2D3CE81-C69C-482A-A239-D3DB146FE5C1Q37515292-FB1CA0F2-FBF0-4833-9A89-39606159CB2AQ37963571-D99ECE04-4F6F-45C2-8A70-B25B37B1F9FEQ38389889-A5BE6DD7-B205-451E-A4EC-A92DD9A4E062Q39158338-B853749D-B284-4CF2-93AB-96A3DED5899DQ39209607-1B134D10-9A30-44B3-9861-3FC4A67D7716Q41546064-79C6ED65-F7C4-450D-8137-B180C442B0FAQ41733975-ACF24E02-309E-4200-906F-061764ADD58AQ41808471-1BFB7499-B569-49BC-B2C1-28EDA8ED3C72Q42517857-896D7338-E4FA-46DD-BD3C-80E1086A2955Q47283583-817E6E28-D4E0-4F49-93A8-DCB9F1E6C81EQ47321232-C9E9EAD7-100E-4848-AEE7-750928B3B3C8Q47377449-24309B98-07CE-4683-A845-A999AF2D8FCAQ47605999-89417EF4-F24F-4D72-B94F-E7BD37DB3DD3Q49914138-B57ED629-0C4F-4720-8AC1-374293AE155EQ53118076-5AF9133A-ABAC-4AD0-B2C7-0C3D25C04978
P2860
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Early effects of olanzapine on ...... n patients with schizophrenia.
@en
Early effects of olanzapine on ...... n patients with schizophrenia.
@nl
type
label
Early effects of olanzapine on ...... n patients with schizophrenia.
@en
Early effects of olanzapine on ...... n patients with schizophrenia.
@nl
prefLabel
Early effects of olanzapine on ...... n patients with schizophrenia.
@en
Early effects of olanzapine on ...... n patients with schizophrenia.
@nl
P2093
P2860
P356
P1476
Early effects of olanzapine on ...... n patients with schizophrenia.
@en
P2093
Akihiko Kase
Akiko Kanai
Hideki Hosojima
Hirotake Uchikado
Koichi Hasegawa
Satoshi Miura
Takashi Togo
Toshinari Odawara
Yoshio Hirayasu
Yuiko Kato
P2860
P356
10.1177/0269881105056647
P407
P577
2005-10-04T00:00:00Z